Pure Global

Safety and Efficacy of MBF-118 in Patients With Crohn Disease - Trial NCT05940558

Access comprehensive clinical trial information for NCT05940558 through Pure Global AI's free database. This Phase 2 trial is sponsored by Medibiofarma S.L. and is currently Recruiting. The study focuses on Crohn Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05940558
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05940558
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety and Efficacy of MBF-118 in Patients With Crohn Disease
A Phase IIa, Open Label, Single-centre Study to Assess the Initial Antifibrotic Efficacy, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of MBF-118 in Crohn's Disease Patients With Stenosis

Study Focus

Crohn Disease

MBF-018 oral capsules

Interventional

drug

Sponsor & Location

Medibiofarma S.L.

Santiago de Compostela, Spain

Timeline & Enrollment

Phase 2

Apr 12, 2023

Apr 01, 2024

10 participants

Primary Outcome

Number of Adverse events

Summary

This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety
 and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on
 top of standard of care.

ICD-10 Classifications

Crohn disease, unspecified
Other Crohn disease
Crohn disease of large intestine
Crohn disease of small intestine
Crohn disease [regional enteritis]

Data Source

ClinicalTrials.gov

NCT05940558

Non-Device Trial